LCZ696 + Valsartan + AHU377 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systolic Hypertension
Conditions
Systolic Hypertension
Trial Timeline
Jan 1, 2011 → Dec 1, 2011
NCT ID
NCT01281306About LCZ696 + Valsartan + AHU377 + Placebo
LCZ696 + Valsartan + AHU377 + Placebo is a phase 2 stage product being developed by Novartis for Systolic Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01281306. Target conditions include Systolic Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01281306 | Phase 2 | Completed |
| NCT00549770 | Phase 2 | Completed |
Competing Products
8 competing products in Systolic Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary | Daiichi Sankyo | Phase 3 | 77 |
| IvabRadine hemisulfate Sustained-release Tablets + placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 65 |
| valsartan, amlodipine, HCTZ + Losartan, HCTZ followed by valsartan, amlodipine, HCTZ | Novartis | Approved | 85 |
| Sacubitril/Valsartan | Novartis | Pre-clinical | 23 |
| Finerenone (Kerendia, BAY94-8862) | Bayer | Phase 3 | 74 |
| Finerenone (Kerendia, BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |
| 6R-BH4 | BioMarin Pharmaceutical | Phase 2 | 49 |